Abstract #2759

Metabolic dynamics of hyperpolarized [1-13C] pyruvate in human prostate cancer

Kristin L Granlund^1,2, Hebert A Vargas¹, Serge K Lyashchenko³, Phillip J DeNoble³, Vincent A Laudone⁴, James Eastham⁴, Ramon A Sosa¹, Matthew A Kennedy¹, Duane Nicholson¹, YanWei W Guo¹, Albert P Chen⁵, James Tropp⁶, Hedvig Hricak^1,2, and Kayvan R Keshari^1,2

¹Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ²Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ³Radiochemistry & Imaging Probes (RMIP) Core, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ⁴Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ⁵GE Healthcare, Toronto, ON, Canada, ⁶GE Healthcare, Fremont, CA, United States

Hyperpolarized (HP) pyruvate has the potential to improve tumor grading and evaluate response to treatment by probing the metabolism of lesions. Three patients with biopsy-proven prostate cancers have been scanned with a 2D dynamic hyperpolarized pyruvate protocol. Repeatability has been evaluated in 2 patients to date. The data from these first 5 injections confirm that HP prostate imaging is feasible and reproducible, and the 2D dynamics will inform 3D static acquisition timing.

This abstract and the presentation materials are available to members only; a login is required.

Join Here